1. Home
  2. CYCU vs NNVC Comparison

CYCU vs NNVC Comparison

Compare CYCU & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc. Common Stock

CYCU

Cycurion Inc. Common Stock

HOLD

Current Price

$4.07

Market Cap

17.8M

Sector

N/A

ML Signal

HOLD

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.33

Market Cap

24.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
NNVC
Founded
2017
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
24.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CYCU
NNVC
Price
$4.07
$1.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.6M
354.8K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,667,874.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.94
52 Week High
$2,045.10
$2.23

Technical Indicators

Market Signals
Indicator
CYCU
NNVC
Relative Strength Index (RSI) 56.31 46.74
Support Level $3.15 $1.07
Resistance Level $4.40 $1.28
Average True Range (ATR) 0.44 0.11
MACD -0.07 0.02
Stochastic Oscillator 62.40 52.38

Price Performance

Historical Comparison
CYCU
NNVC

About CYCU Cycurion Inc. Common Stock

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: